Study to Evaluate Outcomes of Patients Receiving Treatment for Wound Care, Pain Management or Surface Skin Scar Therapy (SOPWS)

January 18, 2016 updated by: Bracane Company
This observational study is designed to evaluate the reported outcomes for patients receiving topical therapy for the treatment of pain, fungal infections or skin scars. The patients will complete the Patient Reported Outcome (PRO) survey monthly and provide valuable data on the patients perception of their health status and well being while receiving therapy.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

This observational study is designed to evaluate the reported outcomes for patients receiving topical therapy for the treatment of pain, fungal infections or skin scars. The patients will complete the Patient Reported Outcome (PRO) survey monthly and provide valuable data on the patients perception of their health status and well being while receiving therapy.

Patients are enrolled for 18 months. The investigator will complete a global patient assessment monthly of the patient's condition.

Study Type

Observational

Enrollment (Actual)

88

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Kentucky
      • Lexington, Kentucky, United States, KY
        • BG Research
    • Tennessee
      • Sevierville, Tennessee, United States, 37862
        • Sevierville Foot and Ankle Clinic
    • Texas
      • Fort Worth, Texas, United States, 76110
        • Associates of Internal Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Must be receiving therapy for pain, wound care or scar therapy

Description

Inclusion Criteria:

  1. An 18 to 85 years old (inclusive) female or male patient
  2. Prescribed compound for the treatment of pain, wound healing or surface skin scar by their Principal Investigator
  3. Any systemic disease (cardiac, renal, or hepatic) must be well controlled.
  4. Has no skin lesions at the site of application of study medication except for wound under treatment
  5. Able to provide informed consent

Exclusion Criteria:

  1. Pregnant or lactating females or women at the child bearing potential not using effective contraception.
  2. Use of other topical or transdermal medication. Patients may be withdrawn for a period of 2 weeks from all topical or transdermal medications prior to study initiation.
  3. Hypersensitivity to local anesthetic or other ingredients of the compounded creams to be used in a study.
  4. Prior reconstruction skin surgery or skin grafts in the area of cream application preventing absorption of cream except for the treatment of surface skin scar
  5. Chronic pain conditions not expected to respond to topical pain medication such as deep abdominal pain, or from conditions such as cancer, or gouty arthritis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in Baseline PRO and Health Status Perception
Time Frame: Up to eighteen (18) months
Up to eighteen (18) months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bracane Company

Collaborators

IFG Medical

Investigators

  • Study Director: Pamela Nelson, RN, MS, Bracane Company
  • Study Chair: Matt Fruge, BS, IFG Medical

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2015

Primary Completion (Actual)

January 1, 2016

Study Completion (Actual)

January 1, 2016

Study Registration Dates

First Submitted

May 8, 2015

First Submitted That Met QC Criteria

May 14, 2015

First Posted (Estimate)

May 15, 2015

Study Record Updates

Last Update Posted (Estimate)

January 20, 2016

Last Update Submitted That Met QC Criteria

January 18, 2016

Last Verified

January 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IFG2015-SOPWS

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe